Telix Pharmaceuticals (ASX:TLX) has announced that preliminary results from the Phase 2 IPAX-Linz study of TLX101 in recurrent high-grade glioma support the patient benefit seen in the IPAX-1 study.
Telix says IPAX-Linz study shows promising efficacy for glioma therapy candidate
April 16, 2025 Australian Biotech
Latest Video
New Stories
-
New partnership promotes buy local for homegrown innovation
May 8, 2025 - - Latest News -
New Zealand to change laws to promote medical conferences
May 8, 2025 - - Latest News -
Australia is about to get a new industry minister
May 8, 2025 - - Latest News -
Internal promotions for new generation of leaders at Astellas
May 7, 2025 - - Latest News -
New study reveals the far-reaching impact of ovarian cancer
May 7, 2025 - - Latest News -
Just the threat of tariffs has secured a quarter of a trillion in investment
May 7, 2025 - - Latest News -
Percheron Therapeutics launches bonus loyalty option offer
May 7, 2025 - - Australian Biotech